Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Source: nct - Country: Israel,Sweden,Germany,United States,Netherlands,Finland,United Kingdom,Belgium,Austria,France - Promoter: nct
nct
Update Il y a 5 ans
A Study of Tasisulam Versus Paclitaxel as Treatment for Metastatic Melanoma
The primary purpose of this study is to see how tasisulam affects metastatic melanoma when compared against paclitaxel as measured by overall survival.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Finland
,
France
,
Germany
,
Israel
,
Italy
,
Korea, Republic of
,
Netherlands
,
Norway
,
Poland
,
Spain
,
Sweden
,
Taiwan, Province of China
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
Country
Australia
,
Austria
,
Belgium
,
Bulgaria
,
Canada
,
Czech Republic
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Poland
,
Romania
,
Russian Federation
,
Serbia
,
Spain
,
Sweden
,
Switzerland
,
Ukraine
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
A Long-term Safety Study of Infliximab (Remicade)
This is a study evaluating the long-term safety of infliximab (Remicade)
Country
Argentina
,
Austria
,
Belgium
,
Canada
,
Denmark
,
Finland
,
France
,
Germany
,
Hungary
,
Ireland
,
Israel
,
Netherlands
,
Norway
,
Poland
,
Spain
,
Sweden
,
Switzerland
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
nct
Update Il y a 5 ans
Repinotan in Patients With Acute Ischemic Stroke
The purpose of this trial is to evaluate Repinotan HCl in patients with acute ischemic stroke. At study entry patients will be randomized to Repinotan HCl or placebo in a 1:1 ratio. The total treatment period wil be 72 hours.
Country
Australia
,
Austria
,
Belgium
,
Canada
,
Finland
,
France
,
Germany
,
Hungary
,
Israel
,
Italy
,
Netherlands
,
Spain
,
Sweden
,
United Kingdom
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1